Product description

is a synthetic peptidomimetic drug consisting of ten amino acids, and acts as an effective and specific antagonist of bradykinin B2 receptors. It has been approved in the EU for use in hereditary angioedema, and is under investigation for a number of other conditions in which bradykinin is thought to play a significant role. Icatibant currently has orphan drug status in the United States and FDA approved on August 25, 2011.  HAE (hereditary angiodysplasia)
Read more


CAS Registry Number 130308-48-4
Categories BiopharmaceuticalsBiopharmaceuticals (general category); APIs (Active Pharmaceutical Ingredients)Peptides
Sales markets Western Europe; Eastern Europe; Asia; North America
Supplied from China

Products from other suppliers